ESMO 2022 Conference Coverage
ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: Pembrolizumab vs. Placebo as 2L Treatment for Sorafenib-Treated aHCC
By
ESMO 2022 Conference Coverage
FEATURING
Julien Edeline
By
ESMO 2022 Conference Coverage
FEATURING
Julien Edeline
Login to view comments.
Click here to Login
GI